Trial · NCT03507686
Results by group346
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 346
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Best-Corrected Visual Acuity (BCVA) as Measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) Chart in Letters at Month 12 | Treatment Period 1: BIIB111 | Study Eye 1 | 68.0 | Standard Deviation 25.18 | letters |
| Mean Best-Corrected Visual Acuity (BCVA) as Measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) Chart in Letters at Month 12 | Treatment Period 2: BIIB111 | Study Eye 1 | 76.5 | Standard Deviation 13.78 | letters |
| Mean Best-Corrected Visual Acuity (BCVA) as Measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) Chart in Letters at Month 12 | Treatment Period 1: BIIB111 | Study Eye 2 | 82.3 | Standard Deviation 8.67 | letters |
| Mean Best-Corrected Visual Acuity (BCVA) as Measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) Chart in Letters at Month 12 | Treatment Period 2: BIIB111 | Study Eye 2 | 81.2 | Standard Deviation 10.82 | letters |
| Ophthalmic Examination Assessment: Mean Intraocular Pressure (IOP) at Month 12 | Treatment Period 1: BIIB111 | Study Eye 1 | 13.5 | Standard Deviation 3.09 | mmHg |
| Ophthalmic Examination Assessment: Mean Intraocular Pressure (IOP) at Month 12 | Treatment Period 2: BIIB111 | Study Eye 1 | 13.5 | Standard Deviation 3.12 | mmHg |
| Ophthalmic Examination Assessment: Mean Intraocular Pressure (IOP) at Month 12 | Treatment Period 1: BIIB111 | Study Eye 2 | 14.9 | Standard Deviation 2.50 | mmHg |
| Ophthalmic Examination Assessment: Mean Intraocular Pressure (IOP) at Month 12 | Treatment Period 2: BIIB111 | Study Eye 2 | 13.5 | Standard Deviation 3.55 | mmHg |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 1: BIIB111 | Cornea: Study Eye 1: Baseline | 0 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 2: BIIB111 | Cornea: Study Eye 1: Baseline | 0 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 1: BIIB111 | Cornea: Study Eye 1: Month 12 | 0 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 2: BIIB111 | Cornea: Study Eye 1: Month 12 | 0 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 1: BIIB111 | Cornea: Study Eye 2: Baseline | 0 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 2: BIIB111 | Cornea: Study Eye 2: Baseline | 0 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 1: BIIB111 | Cornea: Study Eye 2: Month 12 | 0 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 2: BIIB111 | Cornea: Study Eye 2: Month 12 | 0 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 1: BIIB111 | Conjunctiva: Study Eye 1: Baseline | 0 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 2: BIIB111 | Conjunctiva: Study Eye 1: Baseline | 1 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 1: BIIB111 | Conjunctiva: Study Eye 1: Month 12 | 0 | Participants | |
| Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination | Treatment Period 2: BIIB111 | Conjunctiva: Study Eye 1: Month 12 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03507686/results